CRP and COVID-19: We included a homogenized population of patients with severe COVID-19 and administered tocilizumab at the time of clinical and physiological deterioration, as assessed by PaO2/FiO2 < 200 irrespective of levels of non-specific inflammatory markers including CRP and ferritin.